VEGFA and mesothelioma: Recently, the vascular endothelial growth factor (VEGF) antibody (bevacizumab) was added to this standard of care on the basis of a Phase 3 trial (mesothelioma avastin cisplatin pemetrexed study (MAPS)), which showed that this combination improved the overall survival of patients [5].